Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its prostate specific membrane antigen (PSMA)-targeted radioactive in vivo therapeutic drug, 177LuLNC1011. The molecule is intended for evaluation in the treatment of PSMA positive advanced prostate cancer.
Preclinical and investigator-initiated trial (IIT) studies have demonstrated that 177LuLNC1011 exhibits PSMA targeting specificity and high affinity, which enables the concentration of radioactive isotopes within tumor lesions, leading to precise tumor treatment with favorable tolerability. The only similar product currently commercially available globally is Pluvicto from Swiss pharmaceutical giant Novartis, which recorded sales of USD 980 million in 2023 and USD 420 million in the first quarter of 2024.- Flcube.com
